second-line chemotherapy

second-line chemotherapy

Oncology Any chemotherapeutic administered after the agent of choice fails
References in periodicals archive ?
It is a randomised, double-blind, placebo-controlled, multi-centre, POC Phase II study to treat NSCLC patients who have failed second-line chemotherapy.
As both liposomal doxorubicin and the taxane drugs are not available in the public healthcare sector, second-line chemotherapy could not be offered.
Study participants either had relapsed, did not respond to second-line chemotherapy or had relapsed following hematopoietic stem cell transplantation.
Written for clinicians, nurses, researchers, medical students, residents, and fellows, the text opens with an update on prostate cancer prevention followed by chapters covering screening, current surgical approaches to primary prostate cancer treatment, updates on radiation dose escalation, androgen-deprivation therapy (ADT) for advanced prostate cancer, novel androgen receptor therapeutic targets for advanced prostate cancer, metabolic complications of ADT, docetaxel-based chemotherapy in castration-resistant prostate cancer (CRPC), second-line chemotherapy for CRPC, emerging role of immunotherapy in prostate cancer treatment, novel bone-targeted therapy in metastatic CRPC (mCRPC), and emerging treatment strategies for mCRPC.
Patients included in the analysis were either greater than or equal to 60 years old and relapsed or refractory to first-line chemotherapy (Cohort 1, N=25), or greater than or equal to 18 years old and relapsed or refractory to second-line chemotherapy or HSCT (Cohort 2, N=37).
The chapter on controversies in the treatment of Advanced Stage of Small Cell Lung Cancer discusses the controversies in drug regimens and dosages in first-line chemotherapy, prophylactic cranial irradiation after first-line chemotherapy and second-line chemotherapy in these patients.
Interpretation of results must also take into consideration the inclusion within many Japanese study populations of patients with and without measurable disease as well as the high percentage of patients receiving second-line chemotherapy in Japanese studies (approximately 70% versus 30%) compared to Western populations which may partly explain the longer OS results.
The SPARC trial is a double-blinded, randomized, placebo-controlled multinational Phase 3 trial assessing satraplatin plus prednisone as a second-line chemotherapy treatment for patients with HRPC.
Last year, she started a 52-week course of second-line chemotherapy but in May the tumour was shown not to have changed in size.
Last June, she began a 52-week course of second-line chemotherapy, having a scan every three months.
21 involved 731 patients with advanced NSCLC whose cancers had progressed after first- or second-line chemotherapy.